Skip to content
2000
Volume 27, Issue 3
  • ISSN: 1386-2073
  • E-ISSN: 1875-5402

Abstract

Background: The improvements in the treatment of colorectal cancer (CRC) and prolongation of survival time have improved the incidence of bone metastasis. Forkhead box D3 (FOXD3) is involved in the development of CRC. However, the role and mechanism of FOXD3 in CRC bone metastases development are unknown. Objective: Using the combined bioinformatics and cytology experimental analyses, this study aimed to explore the mechanistic role of FOXD3 in the bone metastasis of colon cancer, thereby aiding in the treatment of colon cancer bone metastasis and identification of drug-targeting markers. Methods: First, the changes in the expression levels of the gene and differentially expressed genes (DEGs) between the colon cancer samples and colon cancer metastases were obtained from The Cancer Genome Atlas (TCGA) database. Then, the correlations of the gene with the DEGs were identified. Next, the effects of the on the proliferation and invasion abilities of colon cancer bone metastatic cells were identified using Cell Counting Kit-8 (CCK8) and Transwell cell migration assays, respectively. In addition, Western blot analysis was used to identify the expression levels of the proteins related to the EGFR/Ras/Raf/MEK/ERK (EGFR/ERK) signaling pathway and epithelial-to-mesenchymal transition (EMT). Results: was downregulated in colon cancer and could interact with multiple DEGs in colon cancer bone metastases. gene knockdown could increase the proliferation of human colon cancer bone metastatic cells and their invasive ability. gene knockdown could activate the expression of EGFR/ERK signaling pathway-related proteins and inhibit/promote the expression of EMT-related proteins, which in turn promoted the proliferation and metastasis of LoVo cells from colon cancer bone metastases. Conclusion: Overall, this study demonstrated that the downregulation of the FOXD3 gene might promote the proliferation of colon cancer bone metastatic cell lines through the EGFR/ERK pathway and promote their migration through EMT, thereby serving as a promising therapeutic target.

Loading

Article metrics loading...

/content/journals/cchts/10.2174/1386207326666230505111008
2024-02-01
2025-07-13
Loading full text...

Full text loading...

/content/journals/cchts/10.2174/1386207326666230505111008
Loading

  • Article Type:
    Research Article
Keyword(s): bone metastasis; CRC; EGFR/ERK signaling pathway; EMT; FOXD3; TCGA
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test